Bridgefront Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Bridgefront Capital's VRTX Position: Q2 2026 in Review
Bridgefront Capital opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 760 shares worth $378K. The stake represents 0.1% of the portfolio and ranks #323 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in VRTX as recently as Q3 2025.
Bridgefront Capital first reported a position in VRTX in Q3 2021 and has held it in 5 quarters since. The position peaked at $389K in Q4 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Bridgefront Capital held 760 shares of Vertex Pharmaceuticals worth $378K as of Q2 2026.
- Vertex Pharmaceuticals was a new Bridgefront Capital position in Q2 2026.
- Vertex Pharmaceuticals made up 0.1% of Bridgefront Capital's portfolio in Q2 2026, its #323 holding.
- Bridgefront Capital first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 5 quarters since.
- Bridgefront Capital's Vertex Pharmaceuticals position peaked at $389K in Q4 2024.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.